Ipca Laboratories’ Piparia (Silvassa) formulations manufacturing facility has received Voluntary Action Indicated (VAI) classification from U.S. Food and Drug Administration (USFDA). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regards to current good manufacturing practice (CGMP).
USFDA had conducted inspection at the said manufacturing facility from April 18, 2023 to April 26, 2023, which inspection resulted into 3 observations under USFDA Form 483.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations.
